Back to Search
Start Over
LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
- Source :
-
Annals of Oncology . 2022 Supplement 7, Vol. 33, pS1402-S1403. 2p. - Publication Year :
- 2022
- Subjects :
- *HEPATOCELLULAR carcinoma
*SORAFENIB
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 159078734
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.08.033